 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- ||| VET3-TGI / KaliVir
Enrollment open, Metastases: STEALTH-001: A Study of VET3-TGI in Patients With Solid Tumors (clinicaltrials.gov) - Sep 20, 2024
P1, N=60, Recruiting, Sponsor: KaliVir Immunotherapeutics
Not yet recruiting --> Recruiting
- | VET3-TGI / KaliVir
New P1 trial, Metastases: STEALTH-001: A Study of VET3-TGI in Patients With Solid Tumors (clinicaltrials.gov) - Jun 6, 2024
P1, N=60, Not yet recruiting, Sponsor: KaliVir Immunotherapeutics
- ||| ASP1012 / Astellas
Enrollment open: A Study of ASP1012 in Adults With Solid Tumors (clinicaltrials.gov) - Jan 4, 2024
P1, N=229, Recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| ASP1012 / Astellas
New P1 trial: A Study of ASP1012 in Adults With Solid Tumors (clinicaltrials.gov) - Dec 14, 2023
P1, N=229, Not yet recruiting, Sponsor: Astellas Pharma Global Development, Inc.
- VET3-TGI / KaliVir
Novel oncolytic viral immunotherapy VET3-TGI displays enhanced systemic delivery and inhibits TGFb-signaling while augmenting type-1 immune response in the tumor (Exhibit Hall B) - Sep 27, 2023 - Abstract #SITC2023SITC_1684;
Conclusions Altogether, VET3-TGI demonstrated good ability to counter TGFb1 mediated immunosuppression and dramatically enhanced anti-tumor immune responses leading to safe and potent therapeutic activity in multiple mouse tumor models. Based on the above, VET3-TGI was selected as a lead clinical candidate and clinical manufacture and toxicology testing is undergoing with a human version of this virus.
- VET3-TGI / KaliVir
Novel Oncolytic Therapy VET3-TGI Restricts TGFb1 and Augments Type-1 Immune Response in TME, Leading to Superior Therapeutic Efficacy in Multiple Preclinical Tumor Models (Room 501 ABC) - Apr 6, 2023 - Abstract #ASGCT2023ASGCT_1006;
Based on the above, VET3-TGI is selected as the lead clinical candidate for upcoming clinical trials. Currently, clinical manufacture and toxicology testing is undergoing with a human version of this virus.
- VET3-TGI / KaliVir
The oncolytic virus VET3-TGI both blocks TGF-beta signaling and activates type 2 IFN responses, resulting in potent therapeutic responses in multiple mouse models (Section 44; Poster Board #5) - Mar 14, 2023 - Abstract #AACR2023AACR_8179;
This data led to the selection of VET3-TGI as our lead clinical candidate. A human version of the virus is currently undergoing clinical manufacture and toxicology testing.
- VET3-TGI / KaliVir
A novel oncolytic immunotherapy, VET3-TGI, overcomes TGFB1 mediated immunosuppression, augments type-1 immune response, and displays potent therapeutic activity in multiple mouse tumor models. (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1206;
A human version of the virus is currently undergoing clinical manufacture and toxicology testing. Ethics Approval Animal studies were approved by IACUC, Hilltop animal center